Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EXCEL Outcomes: PCI vs CABG in Patients with Prior Cerebrovascular disease

Most certainly, as we read this title, we imagine the conclusion (as does the editor): patients with prior cerebrovascular disease (CEVD) benefit from a less invasive revascularization strategy, such as PCI. However, the EXCEL outcomes tell us that patients with left main coronary artery disease (LMCAD) and a history of CEVD will not benefit from either one over the other.

Tasa de stroke post cirugía vs angioplastia coronaria en un análisis de más de 10.000 pacientesLogically, it shows this subgroup sees more events than patients with no history of CEVD, but this increased events rate appears indifferent to revascularization type.

 

The EXCEL trial (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) included patients with left main CAD and low and intermediate SYNTAX score randomized to PCI with everolimus eluting stent vs. myocardial revascularization surgery (CABG). Effects of prior CEVD were measured at 30 days and 3 years and were defined as prior stroke, transient ischemic attack, or carotid artery disease.


Read also: TAVR Learning Curve and Volume-Outcomes Relationship Plateau.


Of 1898 patients included in the study, 233 (12.3%) had a history of CEVD. This subgroup presented more comorbidities (including hypertension, diabetes, peripheral artery disease, anemia, chronic kidney disease, or prior PCI) than patients with no history of CEVD.

 

Prior CEVD was associated to nearly three times more strokes, both at 30 days (2.2% vs.0.8%; p=0.05) and at 3 years (6.4% vs. 2.2%; p=0.0003). It was also observed nearly double the combined events rate at 3 years, which included death, stroke or myocardial infarction (25.0% vs. 13.6%; p<0.0001).


Read also: Long-Term Foramen Ovale Closure after Cryptogenic Stroke.


The relative effect of PCI on CEVD rate at 30 days and 3 years, and on the combined events at 3 years, compared against CABG, was consistent both in patients with a history of CEVD and in patients with no history of CEVD.

 

Conclusion

Patients with a history of CEVD and left main CAD present higher CEVD and events rate after revascularization, regardless the strategy.

 

The EXCEL outcomes do not support a revascularization strategy as ‘preferred’ for this group of patients.

 

Original title: Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients with Prior Cerebrovascular Disease. Results from the EXCEL Trial.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...